세계의 생명공학 분야 AI 시장 : 제공 제품별, 기능별, 전개 모드별, 최종사용자별, 지역별 - 예측(-2029년)

The global AI in biotechnology market is projected to reach USD 7.75 billion by 2029 from USD 3.23 billion in 2024, at a high CAGR of 19.1% during the forecast period. The market is expected to grow as a result of the increasing demand for personalized therapies and precision medicines, and the growing applications of AI in epidemiological models for predicting disease outbreaks. It helps public health officials to respond and develop better vaccines which further drives market growth. The increasing demand for personalized therapies and precision medicine has led to an increasing number of clinical trials performed. For instance, as of October 2023, around 1584 clinical trials performed using AI for various diseases were reported to Clincaltrials.gov. However, the limited interpretability of AI algorithms, high implementation cost and data privacy & security concerns are some of the restraining factors for the market growth.

"Based on function, research & development segment dominated the AI in biotechnology market in 2023"

The AI in biotechnology market by function is broadly divided into six segments: research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, and post-market surveillance & patient support. The research & development segment accounted for the largest share of the global AI in biotechnology market in 2023. The large share of this segment can be attributed to the rising demand for personalized medicine, automation in labs, the rise of predictive analytics, and the need for faster drug discovery. an increase in the number of AI-discovered molecules in clinical trials significantly augments market growth. For instance, AI-native Biotechs and their partners in the pharmaceutical industry have entered an increasing number of molecules for AI-driven clinical trials (Source: Elsevier B.V.). In 2023, there were around 67 reported ongoing trials, and this number has increased from 2014 with around 60% year-over-year compound growth.

"In 2023, the pharmaceutical companies held the largest market share among end users."

Based on end user, pharmaceutical companies hold the largest share of the AI in biotechnology market. There are emerging health problems, notably cognitive decline that led to high healthcare services and medication demands, associated with such demographic shifts. Pharmaceutical companies will experience huge growth opportunities as life expectancy increases, thereby raising the increasing healthcare demands of this aging population. Additionally, massive investments are being made by pharmaceutical companies into research and development, particularly drug discovery and development processes wherein AI is utilized for tasks like target identification, lead optimization, and patient stratification in clinical trials.

"In 2023, Europe was the second largest regional market for AI in the biotechnology market."

In 2023, Europe held the second-highest share of the AI in biotechnology market. This dominance is attributed to a substantial increase in investment in Europe for AI, with a growing number of patent filings for biotechnology-related medical technology. In the year 2022, the European Patent Office (EPO) published over 10,000 AI patent applications, which highlights an increased focus on AI solutions in biotechnology. In March 2023, the UK government pledged investment in nine promising AI healthcare technologies to speed up research and development. Moreover, in August 2023, the government launched 22 new projects to explore the application of AI in healthcare. All these initiatives represent Europe's determination to spearhead applications of AI in the biotechnology sector.

The break-down of primary participants is as mentioned below:

• By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
• By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia plc (UK), Schrodinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US), Deep Genomics. (Canada), ), Data4Cure, Inc. (US), Genoox (US), BenevolentAI (US), and DNAnexus, Inc. (US) are some of the key players in the AI in biotechnology market.

The study includes an in-depth competitive analysis of these key players in AI in biotechnology market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

The report analyses the AI in biotechnology market. It aims to estimate the market size and future growth potential of various market segments based on offering (end-to-end solutions, niche solutions, technology providers, and services), function (research & development [R&D], regulatory compliance, manufacturing & supply chain, launch & commercial, post-market surveillance & patient support, and corporate), deployment mode (cloud-based, and on-premise), end-user (pharmaceutical companies, biotechnology companies, research institutes and labs, healthcare providers, and contract research organizations [CRO]), and region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in biotechnology market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, collaborations, acquisitions, expansion, agreements, investment, and product launches associated with the AI in biotechnology market. Competitive analysis of upcoming startups in the AI in biotechnology market ecosystem is covered in this report.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

Analysis of key drivers: (growing cross-industry collaborations and partnerships, growing need to reduce the time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power, and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth), and challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in biotechnology market.
• Market Development: Comprehensive information on the lucrative emerging markets, by offering, function, deployment mode, end-user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market including NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia (UK), Schrodinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US),Deep Genomics. (Canada), Exscientia (US), and Data4Cure, Inc.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from primary experts
• 2.2 MARKET SIZE ESTIMATION
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW
• 4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION
• 4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER & REGION
• 4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT
• 4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing cross-industry collaborations and partnerships
    • 5.2.1.2 Growing need to reduce time and cost of drug discovery and development
    • 5.2.1.3 Rising adoption of AI in precision medicine
    • 5.2.1.4 Improving computing power and declining hardware cost
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies
    • 5.2.2.2 Data privacy risks and compliance challenges for AI in biotechnology
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Integrating AI and big data in precision medicine for biotechnology advancement
    • 5.2.3.2 Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations
    • 5.2.3.3 Innovation across healthcare, agriculture, and environmental science for global growth
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Data quality and interpretability issues that hinder AI integration and trustworthiness
    • 5.2.4.2 AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges
• 5.3 ECOSYSTEM ANALYSIS
• 5.4 CASE STUDY ANALYSIS
  • 5.4.1 LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS
  • 5.4.2 IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION
  • 5.4.3 ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 BARGAINING POWER OF SUPPLIERS
  • 5.6.2 BARGAINING POWER OF BUYERS
  • 5.6.3 THREAT OF SUBSTITUTES
  • 5.6.4 THREAT OF NEW ENTRANTS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 REGULATORY ANALYSIS
  • 5.7.1 REGULATORY LANDSCAPE
    • 5.7.1.1 North America
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
    • 5.7.1.4 Latin America
    • 5.7.1.5 Middle East & Africa
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 PATENT ANALYSIS
  • 5.8.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY
  • 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Natural language processing (NLP)
    • 5.9.1.2 Predictive analytics
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Cloud computing
    • 5.9.2.2 Big data analytics
• 5.10 INDUSTRY TRENDS
  • 5.10.1 EVOLUTION OF AI IN BIOTECHNOLOGY
  • 5.10.2 COMPUTER-AIDED DRUG DESIGN AND AI
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS
  • 5.11.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 BUYING CRITERIA
• 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 END-USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET
  • 5.17.1 KEY USE CASES
  • 5.17.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.17.2.1 Case study: Accelerated biomarker discovery and clinical trial optimization
  • 5.17.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.17.3.1 Drug discovery and development market
    • 5.17.3.2 Genomics and bioinformatics market
    • 5.17.3.3 Medical imaging & diagnostics market
  • 5.17.4 USER READINESS & IMPACT ASSESSMENT
    • 5.17.4.1 User readiness
      • 5.17.4.1.1 Pharmaceutical companies
      • 5.17.4.1.2 Biotechnology companies
    • 5.17.4.2 Impact assessment
      • 5.17.4.2.1 User A: Pharmaceutical companies
        • 5.17.4.2.1.1 Implementation
        • 5.17.4.2.1.2 Impact
      • 5.17.4.2.2 User B: Biotechnology companies
        • 5.17.4.2.2.1 Implementation
        • 5.17.4.2.2.2 Impact

6 AI IN BIOTECHNOLOGY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
• 6.3 NICHE SOLUTIONS
  • 6.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
• 6.4 TECHNOLOGIES
  • 6.4.1 ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
• 6.5 SERVICES
  • 6.5.1 CONSULTING SERVICES
    • 6.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption of consulting services
  • 6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
    • 6.5.2.1 Increasing precision and efficiency in IT support services to boost demand
  • 6.5.3 TRAINING & EDUCATION SERVICES
    • 6.5.3.1 Need for skilled talent to drive market growth
  • 6.5.4 POST-SALES & MAINTENANCE SERVICES
    • 6.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market

7 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION

• 7.1 INTRODUCTION
• 7.2 RESEARCH & DEVELOPMENT
  • 7.2.1 DRUG DISCOVERY
    • 7.2.1.1 Molecular design & optimization
      • 7.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market growth
    • 7.2.1.2 Biomarker discovery
      • 7.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand for
    • 7.2.1.3 Structure-activity relationship (SAR) modeling
      • 7.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth
  • 7.2.2 CLINICAL DEVELOPMENT
    • 7.2.2.1 Trial design
      • 7.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market
    • 7.2.2.2 Site selection
      • 7.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth
    • 7.2.2.3 Recruitment
      • 7.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand
    • 7.2.2.4 Clinical data assessment
      • 7.2.2.4.1 Ability of clinical data assessment to enhance efficiency and accuracy of data interpretation to propel market
    • 7.2.2.5 Predictive toxicity & risk monitoring
      • 7.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates to support market
    • 7.2.2.6 Monitoring & drug adherence
      • 7.2.2.6.1 Enhanced patient compliance with monitoring & drug adherence to drive market growth
    • 7.2.2.7 Real-world evidence (RWE) analysis
      • 7.2.2.7.1 Enhanced safety monitoring & economic evaluation with RWE analysis to propel growth
• 7.3 REGULATORY COMPLIANCE
  • 7.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
• 7.4 MANUFACTURING & SUPPLY CHAIN
  • 7.4.1 SUPPLY CHAIN PLANNING
    • 7.4.1.1 Increasing demand for real-time data analytics to accelerate market growth
  • 7.4.2 INVENTORY MANAGEMENT
    • 7.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel growth
  • 7.4.3 LOGISTICS OPTIMIZATION
    • 7.4.3.1 Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth
  • 7.4.4 DEMAND FORECASTING
    • 7.4.4.1 Ability to integrate data for reliable demand forecasts to fuel growth
  • 7.4.5 PREDICTIVE MAINTENANCE
    • 7.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand
  • 7.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
• 7.5 LAUNCH & COMMERCIAL
  • 7.5.1 LAUNCH COORDINATION
    • 7.5.1.1 Growing product launch success rates through predictive analytics to boost adoption
  • 7.5.2 PATIENT ENGAGEMENT
    • 7.5.2.1 Advantages such as real-time patient feedback for better health outcomes to support growth
  • 7.5.3 MARKETING OPERATIONS
    • 7.5.3.1 Enhanced marketing performance with AI to boost market
  • 7.5.4 PREDICTIVE PRICING
    • 7.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption
• 7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT
  • 7.6.1 MEDICATION ADHERENCE
    • 7.6.1.1 Growing demand for personalized healthcare to drive market
  • 7.6.2 ADVERSE EVENT REPORTING
    • 7.6.2.1 Advantages such as faster post-market surveillance and enhanced drug safety to drive demand
  • 7.6.3 PATIENT MONITORING
    • 7.6.3.1 Rise of remote healthcare solutions to boost demand
  • 7.6.4 COMPLIANCE MONITORING
    • 7.6.4.1 Increasing complexity of regulatory requirements to drive adoption
  • 7.6.5 PATIENT SUPPORT PROGRAMS
    • 7.6.5.1 Growing interest in patient-centered care to support growth
• 7.7 CORPORATE
  • 7.7.1 RISK MANAGEMENT
    • 7.7.1.1 Rising expenditure for drug development to support growth
  • 7.7.2 COMPLIANCE MONITORING
    • 7.7.2.1 Strict guidelines from bodies to aid growth
  • 7.7.3 SALES FORCE OPTIMIZATION
    • 7.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization
  • 7.7.4 OTHER CORPORATE FUNCTIONS

8 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE

• 8.1 INTRODUCTION
• 8.2 CLOUD-BASED SOLUTIONS
  • 8.2.1 PUBLIC CLOUD
    • 8.2.1.1 Need to reduce dependency on expensive on-premise infrastructure to boost demand
  • 8.2.2 PRIVATE CLOUD
    • 8.2.2.1 Need for enhanced security and data protection to drive market growth
  • 8.2.3 MULTI-CLOUD
    • 8.2.3.1 Enhanced flexibility & cost optimization to support market growth
  • 8.2.4 HYBRID CLOUD
    • 8.2.4.1 Cost efficiency and flexibility of hybrid cloud to fuel growth
• 8.3 ON-PREMISE SOLUTIONS
  • 8.3.1 ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH

9 AI IN BIOTECHNOLOGY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL COMPANIES
  • 9.2.1 INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
• 9.3 BIOTECHNOLOGY COMPANIES
  • 9.3.1 ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH
• 9.4 RESEARCH INSTITUTES & LABS
  • 9.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
• 9.5 HEALTHCARE PROVIDERS
  • 9.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
• 9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 9.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH

10 AI IN BIOTECHNOLOGY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Increasing investments and partnerships to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Increased funding in start-ups to drive uptake of AI in biotechnology
  • 10.3.3 UK
    • 10.3.3.1 Increasing investments and government fund allocations to drive market
  • 10.3.4 FRANCE
    • 10.3.4.1 Government initiatives in France to support market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Growing investments to create opportunities for market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan
  • 10.4.3 CHINA
    • 10.4.3.1 Rising foreign investments to drive market in China
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing number of start-ups and support from government to propel market
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Significant advances in AI integration for R&D to fuel growth
  • 10.4.6 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Funding of biotech companies to drive market in Brazil
  • 10.5.3 MEXICO
    • 10.5.3.1 Investment inflows and strengthening AI-related education to drive market in Mexico
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Increase in healthcare investments to support market growth
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.4.1 RANKING OF KEY MARKET PLAYERS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Component footprint
    • 11.5.5.3 Application footprint
    • 11.5.5.4 End-user footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & UPGRADES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 NVIDIA CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 ILLUMINA, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 EXSCIENTIA
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
      • 12.1.3.3.2 Deals
      • 12.1.3.3.3 Other developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 SCHRODINGER, INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product upgrades
      • 12.1.4.3.2 Deals
  • 12.1.5 RECURSION PHARMACEUTICALS, INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
      • 12.1.5.3.2 Expansions
      • 12.1.5.3.3 Other developments
  • 12.1.6 SOPHIA GENETICS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches
      • 12.1.6.3.2 Deals
  • 12.1.7 PREDICTIVE ONCOLOGY
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches
      • 12.1.7.3.2 Deals
      • 12.1.7.3.3 Expansions
  • 12.1.8 BENEVOLENTAI
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
      • 12.1.8.3.2 Other developments
  • 12.1.9 EUROFINS DISCOVERY
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
      • 12.1.9.3.3 Expansions
  • 12.1.10 XTALPI INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
  • 12.1.11 DNANEXUS, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Other developments
  • 12.1.12 NUMEDII, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 BPGBIO, INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches
      • 12.1.13.3.2 Deals
      • 12.1.13.3.3 Other developments
  • 12.1.14 IKTOS
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Deals
      • 12.1.14.3.2 Other developments
  • 12.1.15 INSILICO MEDICINE
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Product approvals
      • 12.1.15.3.2 Deals
      • 12.1.15.3.3 Other developments
  • 12.1.16 LOGICA (CHARLES RIVER + VALO HEALTH)
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Product launches
  • 12.1.17 AMERICAN CHEMICAL SOCIETY
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
  • 12.1.18 AGANITHA AI INC.
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products offered
    • 12.1.18.3 Recent developments
      • 12.1.18.3.1 Deals
      • 12.1.18.3.2 Other developments
• 12.2 START-UP/SME PLAYERS
  • 12.2.1 VERISIM LIFE
  • 12.2.2 VALO HEALTH
  • 12.2.3 TEMPUS AI, INC.
  • 12.2.4 LIFEBIT BIOTECH LTD.
  • 12.2.5 GENOOX
  • 12.2.6 DATA4CURE, INC.
  • 12.2.7 DEEP GENOMICS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS